Quanterix (QTRX) announced the first to market, commercial launch of two novel phospho-tau assays: p-Tau 205 and p-Tau 212, expanding its portfolio of blood-based biomarkers for Alzheimer’s disease and neurodegeneration. The announcement comes alongside Quanterix’s robust presence at the Alzheimer’s Association International Conference 2025, with more than 55 posters and presentations featuring data generated using its Simoa technology.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTRX: